Amedisys (NASDAQ:AMED) Rating Reiterated by Cantor Fitzgerald

Amedisys (NASDAQ:AMED)‘s stock had its “neutral” rating reissued by research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $101.00 price target on the health services provider’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 10.03% from the company’s previous close.

A number of other brokerages have also weighed in on AMED. Royal Bank of Canada increased their price objective on Amedisys from $97.00 to $100.00 and gave the company an “outperform” rating in a report on Monday, March 25th. Raymond James reissued a “market perform” rating on shares of Amedisys in a report on Tuesday, March 26th. Finally, StockNews.com started coverage on Amedisys in a report on Monday, April 8th. They issued a “buy” rating on the stock. Eight investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat.com, Amedisys presently has a consensus rating of “Hold” and an average target price of $97.50.

Amedisys Trading Up 0.7 %

Amedisys stock opened at $91.79 on Thursday. The stock has a 50-day moving average of $92.54 and a two-hundred day moving average of $93.35. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.05 and a current ratio of 1.05. Amedisys has a one year low of $73.10 and a one year high of $96.44. The stock has a market cap of $3.00 billion, a PE ratio of -143.42, a price-to-earnings-growth ratio of 4.28 and a beta of 0.86.

Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Wednesday, April 24th. The health services provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. The company had revenue of $571.41 million during the quarter, compared to analysts’ expectations of $565.38 million. Amedisys had a positive return on equity of 13.00% and a negative net margin of 0.91%. The firm’s revenue was up 2.7% compared to the same quarter last year. During the same period last year, the business posted $1.00 earnings per share. On average, research analysts anticipate that Amedisys will post 4.54 EPS for the current fiscal year.

Institutional Trading of Amedisys

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Banque Cantonale Vaudoise acquired a new stake in Amedisys during the first quarter worth about $60,000. Cetera Trust Company N.A acquired a new stake in Amedisys during the fourth quarter worth about $215,000. CWM LLC grew its holdings in Amedisys by 40.4% during the fourth quarter. CWM LLC now owns 2,629 shares of the health services provider’s stock worth $250,000 after acquiring an additional 757 shares during the period. Contravisory Investment Management Inc. acquired a new stake in Amedisys during the fourth quarter worth about $258,000. Finally, Mesirow Institutional Investment Management Inc. grew its holdings in Amedisys by 9.9% during the fourth quarter. Mesirow Institutional Investment Management Inc. now owns 2,844 shares of the health services provider’s stock worth $270,000 after acquiring an additional 257 shares during the period. 94.36% of the stock is owned by institutional investors and hedge funds.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.